Development of medicines for children in Europe: ethical implications
- PMID: 15698816
- DOI: 10.1016/j.prrv.2004.11.008
Development of medicines for children in Europe: ethical implications
Abstract
Ethics of clinical trials in children have been a longstanding topic for debate. Children are vulnerable, unable to consent to participation in trials from a legal perspective and deserve to be protected. Ethical principles and the European legal framework define the safeguards that need to be put in place in any paediatric trial, be it performed in developed or in developing countries. It was considered that children should not be included in trials for ethical reasons. However, there is an ethical need to study medicines as data obtained in adults cannot be extrapolated to children. It is our collective responsibility to obtain sufficient information to be able to prescribe medicines safely whilst protecting children who are exposed in the trials. Future European paediatric regulations should encourage the development of medicines in high-quality ethical research and ensure availability of information to the public.
Similar articles
-
Ethical issues of clinical trials in children: a European perspective.Arch Dis Child. 2009 Jun;94(6):474-7. doi: 10.1136/adc.2008.149898. Epub 2009 Feb 10. Arch Dis Child. 2009. PMID: 19208673 Review.
-
European survey on ethical and legal framework of clinical trials in paediatrics: results and perspectives.J Int Bioethique. 2008 Sep;19(3):17-48, 121-2. J Int Bioethique. 2008. PMID: 19244940
-
Clinical report--guidelines for the ethical conduct of studies to evaluate drugs in pediatric populations.Pediatrics. 2010 Apr;125(4):850-60. doi: 10.1542/peds.2010-0082. Epub 2010 Mar 29. Pediatrics. 2010. PMID: 20351010
-
Developing paediatric medicines: identifying the needs and recognizing the challenges.J Pharm Pharmacol. 2007 Aug;59(8):1043-55. doi: 10.1211/jpp.59.8.0001. J Pharm Pharmacol. 2007. PMID: 17725846 Review.
-
Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.Eur J Clin Pharmacol. 2002 Nov;58(8):495-500. doi: 10.1007/s00228-002-0511-0. Epub 2002 Sep 25. Eur J Clin Pharmacol. 2002. PMID: 12451425
Cited by
-
Does market exclusivity hinder the development of Follow-on Orphan Medicinal Products in Europe?Orphanet J Rare Dis. 2011 Sep 5;6:59. doi: 10.1186/1750-1172-6-59. Orphanet J Rare Dis. 2011. PMID: 21892964 Free PMC article.
-
Clinical trials in children.Br J Clin Pharmacol. 2015 Mar;79(3):357-69. doi: 10.1111/bcp.12305. Br J Clin Pharmacol. 2015. PMID: 24325152 Free PMC article. Review.
-
Oral medicines for children in the European paediatric investigation plans.PLoS One. 2014 Jun 4;9(6):e98348. doi: 10.1371/journal.pone.0098348. eCollection 2014. PLoS One. 2014. PMID: 24897509 Free PMC article.
-
The role of population PK-PD modelling in paediatric clinical research.Eur J Clin Pharmacol. 2011 May;67 Suppl 1(Suppl 1):5-16. doi: 10.1007/s00228-009-0782-9. Epub 2010 Mar 26. Eur J Clin Pharmacol. 2011. PMID: 20340012 Free PMC article. Review.
-
Did pediatric drug development advance epilepsy treatment in young patients? It is time for new research goals.World J Methodol. 2024 Jun 20;14(2):92371. doi: 10.5662/wjm.v14.i2.92371. eCollection 2024 Jun 20. World J Methodol. 2024. PMID: 38983658 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
